CL2012002124A1 - Polvo de rifaximina que comprende un tamaño de partícula entre 40 y 120 micrómetros; composiciones de liberacion controlada que contienen dicha rifaximina y su proceso de preparación, util para el tratamiento de infección intestinales bacterianas.. - Google Patents

Polvo de rifaximina que comprende un tamaño de partícula entre 40 y 120 micrómetros; composiciones de liberacion controlada que contienen dicha rifaximina y su proceso de preparación, util para el tratamiento de infección intestinales bacterianas..

Info

Publication number
CL2012002124A1
CL2012002124A1 CL2012002124A CL2012002124A CL2012002124A1 CL 2012002124 A1 CL2012002124 A1 CL 2012002124A1 CL 2012002124 A CL2012002124 A CL 2012002124A CL 2012002124 A CL2012002124 A CL 2012002124A CL 2012002124 A1 CL2012002124 A1 CL 2012002124A1
Authority
CL
Chile
Prior art keywords
rifaximin
micrometers
useful
treatment
particle size
Prior art date
Application number
CL2012002124A
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Paola Maffei
Vittoria Lauro
Miriam Barbanti
Dario Braga
Donatela Confortini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002124(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of CL2012002124A1 publication Critical patent/CL2012002124A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Polvo de rifaximina que comprende un tamaño de partícula entre 40 y 120 micrómetros; composiciones de liberación controlada que contienen dicha rifaximina y su proceso de preparación, útil para el tratamiento de infección intestinales bacterianas.
CL2012002124A 2010-03-05 2012-07-31 Polvo de rifaximina que comprende un tamaño de partícula entre 40 y 120 micrómetros; composiciones de liberacion controlada que contienen dicha rifaximina y su proceso de preparación, util para el tratamiento de infección intestinales bacterianas.. CL2012002124A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI2010A000370A IT1398550B1 (it) 2010-03-05 2010-03-05 Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo

Publications (1)

Publication Number Publication Date
CL2012002124A1 true CL2012002124A1 (es) 2012-11-09

Family

ID=42697389

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002124A CL2012002124A1 (es) 2010-03-05 2012-07-31 Polvo de rifaximina que comprende un tamaño de partícula entre 40 y 120 micrómetros; composiciones de liberacion controlada que contienen dicha rifaximina y su proceso de preparación, util para el tratamiento de infección intestinales bacterianas..

Country Status (28)

Country Link
US (2) US8748447B2 (es)
EP (1) EP2542225B1 (es)
JP (1) JP5932669B2 (es)
KR (1) KR101663491B1 (es)
CN (1) CN102781432B (es)
AU (1) AU2011222432B2 (es)
BR (1) BR112012021681A8 (es)
CA (1) CA2787123C (es)
CL (1) CL2012002124A1 (es)
CO (1) CO6551760A2 (es)
DK (1) DK2542225T3 (es)
EA (1) EA022324B1 (es)
ES (1) ES2496771T3 (es)
HK (1) HK1174263A1 (es)
HR (1) HRP20140876T1 (es)
IL (1) IL220792A (es)
IT (1) IT1398550B1 (es)
MX (1) MX2012010233A (es)
NZ (1) NZ602230A (es)
PL (1) PL2542225T3 (es)
PT (1) PT2542225E (es)
RS (1) RS53609B1 (es)
SG (1) SG182523A1 (es)
SI (1) SI2542225T1 (es)
TN (1) TN2012000362A1 (es)
UA (1) UA107208C2 (es)
WO (1) WO2011107970A2 (es)
ZA (1) ZA201205537B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2401282B2 (en) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) * 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) * 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
WO2016019372A1 (en) * 2014-08-01 2016-02-04 Bioxcel Corporation Methods for reformulating and repositioning pharmaceutical data and devices thereof
WO2016063289A2 (en) * 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
EP3236965A1 (en) * 2015-05-08 2017-11-01 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
TR201816080T4 (tr) 2016-03-24 2018-11-21 Sandoz Ag Ri̇faksi̇mi̇n alfa & delta i̇çeren farmasöti̇k bi̇leşi̇m
TR201909029T4 (tr) 2016-03-24 2019-07-22 Sandoz Ag Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler.
RS63751B1 (sr) 2016-09-30 2022-12-30 Salix Pharmaceuticals Inc Čvrsti disperzioni oblici rifaksimina
WO2020208140A1 (en) * 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
WO2023067485A1 (en) * 2021-10-19 2023-04-27 Zydus Lifesciences Limited Pharmaceutical combinations

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
DE3113139A1 (de) 1981-04-01 1982-10-21 Smit Transformatoren B.V., 6500 Nijmegen "trockentransformator oder drosselspule mit luftkuehlung"
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
JP3350861B2 (ja) 1990-06-29 2002-11-25 アベンテイス・バルク・ソチエタ・ペル・アチオニ リファペンチンの純粋の結晶型
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
KR100467532B1 (ko) 1996-10-16 2005-01-24 피에스 팔마큐티칼스 인코퍼레이션 프로안토시아니딘 중합체로 된 항-설사 장용피 조제물
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1330427A1 (en) 2000-10-31 2003-07-30 Ciba SC Holding AG Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101480732B1 (ko) * 2006-09-22 2015-01-21 씨아이피엘에이 엘티디. 리팍시민
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
EP3714878B1 (en) 2007-07-06 2022-01-19 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
MX2010009389A (es) 2008-02-25 2010-11-22 Salix Pharmaceuticals Ltd Formas de rifaximina y sus usos.
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
CA2778181A1 (en) 2009-10-26 2011-05-05 Thomas Julius Borody Therapy for enteric infections
US20120214833A1 (en) 2009-10-27 2012-08-23 Lupin Limited Solid dispersion of rifaximin
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
CN102724960A (zh) 2009-11-23 2012-10-10 希普拉有限公司 局部泡沫组合物
US20130202654A1 (en) 2009-11-23 2013-08-08 Cipla Limited Topical Foam Composition
EP2401282B2 (en) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
SG10201507035UA (en) 2010-06-03 2015-10-29 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
WO2011156897A2 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
EA033370B1 (ru) 2010-07-12 2019-10-31 Salix Pharmaceuticals Ltd Составы рифаксимина и их применение
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ES2682965T3 (es) 2011-02-11 2018-09-24 Salix Pharmaceuticals, Ltd. Formas de rifaximina y sus usos
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k

Also Published As

Publication number Publication date
US8748447B2 (en) 2014-06-10
HK1174263A1 (en) 2013-06-07
HRP20140876T1 (hr) 2014-10-24
UA107208C2 (uk) 2014-12-10
ES2496771T3 (es) 2014-09-19
US9498442B2 (en) 2016-11-22
EP2542225B1 (en) 2014-08-20
CN102781432A (zh) 2012-11-14
RS53609B1 (en) 2015-04-30
US20140235662A1 (en) 2014-08-21
MX2012010233A (es) 2012-10-10
EP2542225A2 (en) 2013-01-09
ITMI20100370A1 (it) 2011-09-06
JP2013521273A (ja) 2013-06-10
IL220792A (en) 2015-07-30
ZA201205537B (en) 2013-09-25
IL220792A0 (en) 2012-08-30
PL2542225T3 (pl) 2015-02-27
CA2787123C (en) 2014-10-14
CN102781432B (zh) 2014-12-10
CO6551760A2 (es) 2012-10-31
PT2542225E (pt) 2014-10-13
EA201290734A1 (ru) 2013-04-30
BR112012021681A8 (pt) 2017-12-26
WO2011107970A2 (en) 2011-09-09
IT1398550B1 (it) 2013-03-01
DK2542225T3 (da) 2014-11-17
CA2787123A1 (en) 2011-09-09
EA022324B1 (ru) 2015-12-30
KR20130028901A (ko) 2013-03-20
BR112012021681A2 (pt) 2017-10-31
SI2542225T1 (sl) 2014-12-31
AU2011222432A2 (en) 2012-12-06
WO2011107970A3 (en) 2012-01-05
SG182523A1 (en) 2012-08-30
AU2011222432B2 (en) 2014-05-01
US20130004576A1 (en) 2013-01-03
NZ602230A (en) 2013-11-29
TN2012000362A1 (en) 2014-01-30
JP5932669B2 (ja) 2016-06-08
AU2011222432A1 (en) 2012-08-09
KR101663491B1 (ko) 2016-10-14

Similar Documents

Publication Publication Date Title
CL2012002124A1 (es) Polvo de rifaximina que comprende un tamaño de partícula entre 40 y 120 micrómetros; composiciones de liberacion controlada que contienen dicha rifaximina y su proceso de preparación, util para el tratamiento de infección intestinales bacterianas..
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
IN2015DN00694A (es)
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
MY156697A (en) Modified tuberculosis antigens
PH12014501991A1 (en) Phenicol antibacterials
UA111972C2 (uk) Вагінальна таблетка, яка містить рифаксимін, спосіб її виготовлення та застосування для лікування вагінальних інфекцій
WO2014144295A8 (en) Ceftolozane antibiotic compositions
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
ECSP11011558A (es) Nuevos compuestos químicos.
AU2015352440B2 (en) Compounds
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
GEP201606595B (en) (r) -nifuratel, its use for the treatment of infections and synthesis of (r) and (s) –nifuratel
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP2590652A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING VANOXERIN
IN2015DN02109A (es)
PH12015500518A1 (en) Tricyclic tetrahydroquinoline antibacterial agents
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
CL2015001781A1 (es) Compuestos derivados de ne-81,3-benzoxazol/benzotiazol-2-il)metandiamina; proceso de preparación; composicion farmaceutica y su proceso de preparacion; combinacion farmaceutica; y su uso para el tratamiento de una infeccion micobacteriana como mycobaterium tuberculosis